Overactive Bladder Treatment Market (By Type: Anticholinergics, Mirabegron, Neuromodulation, Botox; By Disease Type: Idiopathic, Neurogenic; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The global overactive bladder treatment market size was estimated at around USD 4.01 billion in 2023 and it is projected to hit around USD 6.43 billion by 2033, growing at a CAGR of 4.85% from 2024 to 2033.

Key Pointers

• North America led the market with the largest market share of 37% in 2023.
• By Type, the mirabegron, a drug, held the largest revenue share of 28% in 2023.
• By Disease Type, the idiopathic OAB segment generated the maximum market share of 79% in 2023.
• By Distribution Channel, the retail pharmacies segment secured the largest market share at 48% in 2023.

Overactive Bladder Treatment Market Overview

The overactive bladder (OAB) treatment market is witnessing a notable surge in growth and development, driven by an increasing prevalence of OAB and a growing focus on enhancing patient outcomes. This overview provides insights into the key factors shaping the landscape of OAB treatment, including market trends, key players, and therapeutic modalities.

Overactive Bladder Treatment Market Growth

The growth of the overactive bladder (OAB) treatment market is propelled by various factors contributing to its expansion. Firstly, the increasing prevalence of overactive bladder, particularly among the aging population, underscores the heightened demand for effective treatment options. Pharmaceutical innovations, marked by the development of novel medications and formulations, play a crucial role in shaping the market landscape. The continuous exploration of technological advancements in medical devices, including neuromodulation devices and implantable neurostimulators, adds a layer of sophistication to OAB treatment, attracting both patients and healthcare providers. Furthermore, the industry's acknowledgment of holistic approaches to OAB management, encompassing lifestyle modifications and behavioral therapies, contributes to a more comprehensive and patient-centric care paradigm. Despite challenges such as regulatory complexities, the market's growth is sustained by a commitment to addressing these issues through collaborative efforts and strategic partnerships. Overall, the convergence of these growth factors positions the Overactive Bladder Treatment Market on a trajectory of sustained expansion, offering promising prospects for improved patient outcomes and quality of life.

Report Scope of the Overactive Bladder Treatment Market

Overactive Bladder Treatment Market Dynamics

Drivers

• Increasing Prevalence of Overactive Bladder (OAB): The primary driver for the growth of the overactive bladder treatment market is the rising incidence of OAB, particularly among the aging population. The expanding demographic of individuals grappling with overactive bladder symptoms fuels the demand for effective treatment options.
• Pharmaceutical Innovations: Continuous advancements in pharmaceuticals, characterized by the development of new medications and formulations, drive market growth. Innovations in antimuscarinics and beta-3 adrenergic agonists cater to diverse patient needs, providing improved efficacy and reduced side effects.

Restraints

• Limited Awareness and Diagnosis: Limited awareness about overactive bladder and challenges in accurate diagnosis act as restraints. A lack of awareness among both healthcare professionals and the general public can result in underdiagnosis or delayed diagnosis, hindering the timely initiation of appropriate treatments.
• Side Effects and Tolerability Issues: Despite pharmaceutical innovations, some OAB medications may be associated with side effects or tolerability issues. Patient reluctance to adhere to treatments due to adverse effects can impact the market, affecting the overall adoption and success of certain therapeutic interventions.

Opportunities

• Innovative Therapeutic Approaches: The overactive bladder treatment market presents opportunities for the development of innovative therapeutic approaches. Ongoing research can lead to the discovery of novel medications, targeted at addressing overactive bladder symptoms with enhanced efficacy and minimal side effects, thereby diversifying treatment options.
• Advancements in Medical Devices: Opportunities lie in the continued advancements of medical devices for overactive bladder treatment. Further research and development in neuromodulation devices, implantable neurostimulators, and other technologies offer the potential for more sophisticated and personalized treatment modalities, expanding choices for patients and healthcare providers.

Type Insights

Segmented by type, the market encompasses anticholinergics, mirabegron, Botox, neuromodulation, and other categories. Mirabegron, a drug, held the largest revenue share of 28% in 2023. Administered as an extended-release oral tablet, mirabegron effectively addresses symptoms associated with overactive bladder. Its widespread application in managing urge urinary incontinence, urgency, frequent urination, coupled with increasing regulatory approvals, is anticipated to propel its demand. Notably, mirabegron's adverse effects, as reported by the National Library of Medicine in September 2022, are generally mild and well-tolerated, establishing it as a safe and efficacious drug.

Furthermore, regulatory bodies are endorsing mirabegron for treating overactive bladder and other related conditions. A significant development occurred in March 2021 when the U.S. FDA granted approval for mirabegron tablets (Myrbetriq) and mirabegron oral suspension (Myrbetriq Granules) to treat neurogenic detrusor overactivity (NDO) in children aged three years and older. Such regulatory endorsements are poised to stimulate the growth of this drug segment throughout the forecast period.

The neuromodulation segment is expected to witness substantial growth, characterized by a notable Compound Annual Growth Rate (CAGR). This growth is attributable to the increasing adoption of sacral and other neuromodulation devices. Sacral neuromodulation (SNM), recognized for its minimally invasive and fully reversible nature, has gained traction as a therapy. Additionally, various neuromodulation techniques, including peroneal neuromodulation and parasacral transcutaneous neuromodulation, have been explored, as highlighted in a study published by the National Library of Medicine in October 2023. These investigative techniques have demonstrated promising results in alleviating symptoms associated with overactive bladder, contributing to the anticipated growth of the neuromodulation segment.

Disease Type Insights

The market is categorized based on disease type into neurogenic overactive bladder and idiopathic overactive bladder. In 2023, the idiopathic OAB segment generated the maximum market share of 79%. This prevalence is primarily attributed to the condition's high occurrence. Idiopathic or non-neurogenic OAB refers to a state where individuals lack a defined or identifiable neurological abnormality, yet experience dysfunction in the bladder nerve pathways. Government authorities' increased focus on idiopathic OAB is expected to propel the growth of this segment in the forthcoming years. Notably, the American Urological Association, in a September 2019 article, amended guidelines for non-neurogenic overactive bladder to establish a clinical framework for disease diagnosis and treatment.

The neurogenic OAB segment is poised to register a lucrative CAGR from 2024 to 2033. The market growth is driven by the heightened attention from public and private entities towards developing innovative solutions for neurogenic OAB. Companies are actively introducing novel drugs tailored for treating overactive bladder in the context of neurologic disorders. For instance, in February 2021, Allergan, now an AbbVie company, obtained U.S. FDA authorization for Botox, a neurotoxin specifically designed to address detrusor overactivity associated with neurologic disorders in pediatric patients.

Distribution Channel Insights

The market is divided based on distribution channels into retail pharmacies, hospital pharmacies, and others. The retail pharmacies segment secured the largest market share at 48% in 2023. This dominance is attributed to the presence of well-established pharmacy chains like Walgreens, Walmart, Rite Aid, CVS Pharmacy, and Kroger, playing a significant role in the segment's expansion. Furthermore, retail pharmacies, including retail pharma stores, provide personalized guidance from pharmacists and offer a diverse array of products, enhancing the overall customer experience. These advantages associated with retail pharmacies are expected to drive the segment's growth throughout the forecast period.

Conversely, the "other" segment, encompassing drug distribution through e-commerce platforms or online channels, is projected to register the fastest CAGR from 2024 to 2033. The surge in players offering online drug services is a key factor propelling the growth of this segment. Notably, major online platforms like Amazon provide products such as Ultimate Bladder Control capsules and MASON NATURAL Daily Bladder Comfort, catering to the control of overactive bladder and urgency. E-commerce platforms offer various advantages, including convenient shopping, time savings, and attractive discounts. These benefits associated with the "other" segment are anticipated to foster rapid growth over the forecast period.

Regional Insights

North America led the market led the market with the largest market share of 37% in 2023. This prominence is attributed to the strong presence of key industry players such as Pfizer, Inc., AbbVie, Inc., and Viatris, Inc., contributing significantly to the region's higher revenue share. Moreover, various companies in the region are actively engaged in clinical trials and expanding their product pipelines. An example of this is the development of Onabotulinumtoxin A (Botox) by Viatris Inc., as highlighted in the JP Morgan Healthcare Conference in January 2023. This under-development product aims to address OAB and cervical dystonia and is expected to be launched by 2026, signaling potential growth for the region over the forecast period.

The Overactive Bladder treatment market in the Asia Pacific region is anticipated to experience a notable CAGR from 2024 to 2033. The significant demand for OAB medications and treatments is driven by the rising prevalence of the condition across the region. Additionally, the introduction of new products and the presence of a large number of industry participants further support the regional market. For instance, in November 2021, Taiho Pharmaceutical Co., Ltd. introduced BUP-4 LADY, an over-the-counter (OTC) medication for urinary urgency in Japan. The product was launched at non-dispensing pharmacies, drug stores, and dispensing pharmacies, contributing to the dynamic growth of the market in the Asia Pacific region.

Key Companies

• Pfizer, Inc
• AbbVie Inc.
• Astellas Pharma Inc.
• Medtronic
• Sumitomo Pharma America, Inc.(Urovant Sciences.)
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Hisamitsu Pharmaceutical Co. Inc.
• Macleods Pharmaceuticals Ltd.
• Endo International plc

Overactive Bladder Treatment Market Segmentations:

By Type

• Anticholinergics
• Mirabegron
• Botox
• Neuromodulation
• Other

By Disease Type

• Idiopathic Overactive Bladder
• Neurogenic Overactive Bladder

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)